Stockwinners Market Radar for January 12, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:37 EST Cathie Wood's ARK Investment bought 41.1K shares of Exact Sciences today

20:35 EST Cathie Wood's ARK Investment bought 70.3K shares of Zoom Video today

17:48 EST Adagio Therapeutics spikes higher after report on ADG20 against Omicron - Shares of Adagio Therapeutics are up approximately 23% or $1.33 per share to approximately $7.22 in after-hours trading on Wednesday after reporting recent findings reported in three separate publications that show ADG20, its lead monoclonal antibody, mAb, has neutralization activity against the Omicron variant of SARS-CoV-2, and outlined initiatives to address current and future SARS-CoV-2 variants of concern. Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. Adagio is engaging with the U.S. Food and Drug Administration, FDA, regarding potential protocol updates to its global Phase 2/3 clinical trials, including an increased dose of ADG20 for the potential prevention and treatment of COVID-19 resulting from the Omicron variant.

17:32 EST KB Home sees Q1 housing revenue $1.43B-$1.53B - Sees Q1 average selling price $472,000. Sees FY22 average selling price $480,000-$490,000. Sees FY22 gross margin 26%. Sees Q1 gross profit margin 22%-26%. Sees FY22 gross profit margin 25.4%-26.2%. Sees Q1 and FY22 effective tax rate 25%. Says expects Q1 community count to remain relatively flat. Says expects to end 2022 with 265 communities. Says foresees strong spring selling season. Says expects to end the quarter with net orders down mid-single digit percentage range year-over-year. Says continues to expect favorable housing market conditions. Comments and guidance taken from Q4 earnings conference call.

16:47 EST Preformed Line Products Co acquires Maxxweld Conectores Eletricos Ltda - Preformed Line Products Company announced that it has acquired Maxxweld Conectores Eletricos Ltda. Founded in 1991 and based out of Curitiba, Brazil, Maxxweld designs and manufactures substation connector systems and accessory hardware for high voltage AC systems and is a market leader in Brazil. The acquisition of Maxxweld will greatly expand PLP's operational and technical capabilities in the region while supporting its overall global substation strategy. Terms of the transaction were not disclosed.

16:41 EST AngioDynamics CEO buys $228K in common stock - In a regulatory filing, AngioDynamics disclosed that its CEO James Clemmer bought 10K shares of common stock on January 11th in a total transaction size of $228.4K, boosting his stake by about 3%. Shares of AngioDynamics are up 2% at $22.52 in after-hours trading.

16:33 EST HCI Group postpones TypTap Insurance Group IPO - HCI Group "announced an update regarding the previously announced initial public offering of its subsidiary, TypTap Insurance Group". CEO Paresh Patel says: "In light of recent market conditions, HCI's Board of Directors determined that current market pricing for the planned offering does not accurately reflect TypTap's value. Our primary objective has been and will continue to be maximizing the value and opportunity of TypTap. We believe we have the resources to execute TypTap's growth plan without the funds raised from an IPO. We will continue to monitor market conditions over the next several quarters and will move forward with a TypTap IPO when and if conditions are appropriate."

16:31 EST Victory Capital reports total AUM $183.7B on December 31, 2021 - The company also reported that net flows were negative during the fourth-quarter period.

16:23 EST UMH Properties increases quarterly dividend 5.3% to 20c per share - The board of directors of UMH Properties announced that its board of directors approved a 5.3% increase in the company's quarterly common stock dividend, raising it to 20c per share from 19c per share. The dividend is payable March 15 to shareholders of record at the close of business on February 15. This represents an annual dividend rate of 80c per share.

16:18 EST Puma Biotechnology's NERLYNX included in NCCN guidelines for breast cancer - Puma Biotechnology "announced that the National Comprehensive Cancer Network, or NCCN, Clinical Practice Guidelines in Oncology for the treatment of breast cancer have been updated for 2022 and include two important changes involving neratinib, or NERLYNX. The first update added NERLYNX to the body of the guidelines for the treatment of adjuvant HER2-positive Breast Cancer under the heading Useful in Certain Circumstances, with a recommendation for considering extended adjuvant neratinib for patients with HR-positive, HER2-positive disease with a perceived high risk of recurrence. The second update involved the inclusion of dose escalation as an approach to improve the tolerability of neratinib in the treatment of adjuvant HER2-positive Breast Cancer. This update aligns with the labeling supplement to the U.S. Prescribing Information approved by the U.S. Food and Drug Administration in June 2021, which incorporated the use of NERLYNX dose escalation as evaluated in the Phase II CONTROL study."

16:15 EST KB Home reports Q4 home deliveries up 28% y/y at 3,679 - Reports Q4 average selling price increased 9% y/y to $451,100.

16:13 EST IAC reports December Angi revenue up 16% from last year - As part of its December monthly metrics disclosure, IAC also reports Dotdash revenue up 5%, and its Search business revenue up 47% from last year. Emerging & Other revenue was up 69% from last year. Reference Link

16:09 EST Decarbonization Plus Acquisition Corp. II approves Tritium combination - Decarbonization Plus Acquisition Corporation II's (DCRN) stockholders voted to approve the business combination with Tritium Holdings and all other proposals presented at DCRN's special meeting of stockholders on January 12. Approximately 96.6% of the votes cast and 58% of the outstanding shares of common stock of DCRN were in favor of approving the business combination proposal. The business combination is expected to close on January 13. The ordinary shares and warrants of Tritium, the going-forward public company, are expected to commence trading on the NASDAQ under the symbols "DCFC" and "DCFCW," respectively, on January 14. Founded in 2001, Tritium designs and manufactures proprietary hardware and software to create advanced and reliable DC fast chargers for electric vehicles.

16:05 EST Elastic promotes Ashutosh Kulkarni to CEO - Elastic announced the promotion of Ashutosh Kulkarni to CEO and his nomination to the Board of Directors. Kulkarni will succeed Founder and CEO Shay Banon, who reassumes the role of Chief Technology Officer, and will continue to serve on the Board of Directors. Banon, who served as CTO prior to being named CEO five years ago, stepped down from his role as Chairman of the Board. Chetan Puttagunta, currently Lead Independent Director, has been appointed Chairman.

16:01 EST Planet Labs to launch 44 SuperDove satellites on SpaceX's Falcon 9 rocket - Planet Labs PBC announced that the launch of their Flock 4x, consisting of 44 SuperDove satellites, will take place on Thursday, January 13th on SpaceX's Falcon 9 Transporter-3 SSO. This marks the first satellite launch under Planet's new multi-year, multi-launch rideshare agreement with SpaceX. Planet operates the world's largest constellation of Earth observation satellites; and with this launch, the company will have more than 240 satellites in orbit. Flock 4x is set to replenish their existing SuperDove fleet which makes up a portion of the larger constellation. "We are thrilled to be launching our latest flock with SpaceX. Their reliability and leadership in the launch market makes them a natural choice for this mission. Flock 4x will provide the PlanetScope constellation with the latest and strongest capabilities to help meet customer needs," said Planet CEO Will Marshall.

14:42 EST Moderna expects to report COVID-19 data on vaccines in children 2-5 in March - Moderna issued the following statement: "The U.S. FDA requested additional participants at a given dose level in pediatric cohorts after the VRBPAC review of requirements for pediatric EUA on June 10, 2021, and Moderna complied at that time. Outside the United States, Moderna has received regulatory authorizations in Europe, UK, Australia, and Canada for adolescents 12-17 years of age, and has submitted applications for 6-11 years of age. In early December, Moderna also decided to evaluate the potential of lower doses to meet regulatory guidance for immunogenicity in children 6-11 years of age and in adolescents 12-17 years of age in our ongoing clinical trials. The company is also evaluating a booster dose in adolescents 12-17 years of age. The company is in the process of implementing those various protocol amendments. We expect to report data in children 2-5 years of age in March. If the data is supportive and subject to regulatory consultation, Moderna may proceed with regulatory filings for children 2-5 years of age thereafter."

14:03 EST Phibro Animal Health 'welcomes' FDA hearing on Mecadox - Phibro Animal Health reports that the Food and Drug Administration provided notice in the Federal Register of its intention to hold a public hearing regarding Mecadox, which the company said "has been approved and sold in the United States for 50 years and is a widely used treatment for controlling bacterial diseases in swine, including Salmonella and swine dysentery, resulting in improved health and welfare for newly born and young pigs." The hearing will be hosted by the FDA and will take place on March 10, said the company, which noted that the agency will be seeking data and information related to the safety of the product. "We welcome CVM's decision to hold this hearing and hope that the Agency will take stakeholder input into consideration, engaging with scientists, swine producers, and others regarding the safety and unique and unparalleled efficacy of carbadox for half a century. We understand FDA has put the 2020 Proposed Order on hold. We are confident that this hearing will affirm and support the continued safe use of carbadox in the market. In the event that following this hearing FDA continues to assert that the carbadox should be removed from the market, Phibro is entitled to and expects to have a full evidentiary hearing on the merits before an administrative law judge. Mecadox continues to be available for use by our customers. Phibro will continue to defend swine producers' ability to use Mecadox to protect the health and welfare of their animals and is confident that it will be able to reaffirm that the use of carbadox is safe as approved," stated in its press release announcing the Federal Register notice.

14:02 EST Nucor to buidl new sheet mill in Mason County, West Virginia - Nucor Corporation announced that it will build its new state-of-the-art sheet mill in Mason County, West Virginia. When fully operational, the new mill will employ approximately 800 full-time teammates, Nucor said in a statement. "Following a thorough process to determine the right location for our state-of-the-art, greenfield sheet mill, we are thrilled to make this significant investment in West Virginia and enhance our presence in this important region," said Leon Topalian, President and CEO.

12:42 EST 2021 NFL season averaged 17.1M viewers - The National Football League said that the 2021 NFL regular season averaged 17.1M viewers (TV+Digital) - the highest regular season average since 2015 and up +10% vs. 2020. During the 2021 NFL regular season, NFL games ranked as the top 16, 48 of the top 50 and 91 of the top 100 telecasts on TV. Throughout the season, there were 370B total minutes consumed which is up +18% vs. 2020 and the second-highest total on record behind only 2015. For the first time, each NFL team played 17 regular season games, providing fans with an extra week of regular season NFL action. Companies that broadcast NFL games include ViacomCBS (VIACA), Fox (FOXA), Disney (DIS), and Comcast (CMCSA). Companies in the sports betting space include Accel Entertainment (ACEL), Bally's (BALY), Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Genius Sports (GENI), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), Rush Street Interactive (RSI), Scientific Games (SGMS), Score Media (SCR) and Wynn Resorts (WYNN). Reference Link

12:01 EST Volaris transported 2.6M passengers in December - Volaris reports its December 2021 preliminary traffic results. In December 2021, passenger demand in the domestic Mexican and international markets for Volaris increased 34.9% and 10.8%, respectively, as compared to December 2019. The company said it capitalized on the strong market demand to add capacity, both domestically and internationally, while maintaining a high load factor. In December 2021, Volaris transported 2.6 million passengers, 31% higher than the pre-pandemic levels. Volaris said: "For the first quarter 2022, the capacity we currently have on sale represents an ASM growth of approximately 3% compared to the fourth quarter of 2021, implying around 53% ASM growth versus the first quarter of 2021. However, as we have demonstrated since the beginning of the pandemic, we will continue to actively manage capacity and will react accordingly if we observe a deterioration in demand in our markets associated with the omicron variant."

12:00 EST Nam Tai Property falls -15.0% - Nam Tai Property is down -15.0%, or -$1.73 to $9.80.

12:00 EST United States Natural Gas Fund rises 11.7% - United States Natural Gas Fund is up 11.7%, or $1.64 to $15.71.

12:00 EST Fathom rises 27.5% - Fathom is up 27.5%, or $1.46 to $6.77.

11:45 EST Rumble announces 'new highs' for January 3-9 user engagement - Online video platform Rumble announced on Tuesday that it reached new highs for user engagement during the week of January 3rd to 9th, 2022. The company posted record weekly video bandwidth consumption and also saw the most-ever videos uploaded to the platform in a week, it said in a blog post."These records come on the heels of multiple announcements from last week, including the decision by Senator Rand Paul to drop YouTube in favor of Rumble and the announcement by Matt Kohrs, a popular financial livestreaming voice and one of the largest creators by Super Chat revenue on YouTube, to make Rumble and Locals his preferred platforms." Reference Link

10:48 EST Safety announces board refreshment, corporate governance enhancement plan - Safety Insurance Group announced its latest measures as part of its ongoing board refreshment and corporate governance enhancement plan being implemented by Safety's Board of Directors: Increasing the size of the board from six to seven members, Continuation of our board refreshment and corporate governance enhancement plan with an ongoing search for highly qualified director nominees, Appointment of a lead independent director, Appointment of a new chair to the Nominating and Governance Committee, and Adoption of three-year term limits for the chairperson role of the key board committees. As part of a thorough review of board refreshment best practices and policies that began over three years ago, the Board unanimously approved the increase in the number of board seats from six to seven. Starting in August 2021, the Board has been evaluating highly qualified independent nominees and expects to be able to make an announcement with an update on board refreshment prior to the 2022 annual meeting. The Board will present its recommended slate of director nominees in the proxy materials that will be filed with the Securities and Exchange Commission and distributed to stockholders. The Board has appointed Thalia Meehan to the newly created role of Lead Independent Director. The Board has adopted three-year term limits for chairperson of the three key board committees, which will apply to the current chairs as follows: Mary Moran has assumed the chair of the Nominating and Governance Committee for a term that will end at the 2025 annual shareholder meeting; Thalia Meehan's term as chair of the Compensation Committee will end at the 2024 annual shareholder meeting; and Peter Manning's term as chair of the Audit Committee will end at the 2023 annual shareholder meeting. The Company expects to announce its fourth quarter and year end 2021 financial results during the last week of February. The Company's 2022 annual meeting of stockolders has not yet been scheduled, and stockholders are not required to take any action at this time.

10:03 EST Kraft Heinz appoints North America Zone chief strategy, transformation office - The Kraft Heinz Company (KHC) announced the appointment of Dafne Hefner to the newly created role of Chief Strategy & Transformation Officer - North America Zone, effective Jan. 18, 2022. Hefner is being hired to help accelerate the strategic growth plan in the Company's U.S. and Canada businesses, including the broader deployment of Agile teams and a North America Zone digital agenda. Hefner joins Kraft Heinz from Anheuser-Busch InBev SA/NV (BUD), where she most recently served as Senior Vice President of Strategy & Insights.

10:01 EST Izea awarded $1.7M managed services contract - Izea announced that it has been awarded a $1.7M Managed Services contract by a leading provider of online educational services, an existing client of the company. IZEA's network of creators will be producing custom content to increase brand exposure and traffic for the company. The contract was awarded in January and the program will run throughout the calendar year.

10:00 EST Nam Tai Property falls -10.4% - Nam Tai Property is down -10.4%, or -$1.20 to $10.33.

10:00 EST Zendesk holder Janus Henderson 'gravely concerned' about Momentive deal - Janus Henderson last night disclosed a letter sent to the board of Zendesk (ZEN), which stated in part: "We engaged in an open dialogue with Zendesk management and the Board of Directors over the past two months since the announcement of the proposed acquisition of Momentiv, on October 28, 2021. We are especially grateful for the BoD engagement and willingness to discuss our concerns. Our multiple conversations suggest there is an understanding of shareholder concern and respect given to shareholders. However we are writing this letter to share our concerns in hopes of continued dialogue and understanding of our position...We believe we speak from a perspective of deep understanding of customer service, customer experience and interaction. From that perspective, we question the strategic, tactical, and financial rationale to the proposed deal: We do not think there is a strategic advantage for ZEN to own MNTV...We are gravely concerned about the strategic, tactical, and financial rationale of this proposed deal. We think the company should instead renew its focus on executing on the ZEN standalone business. We are writing this letter to ensure both management and the Board of Directors fully understand our stance. While we appreciate the dialogue with both management and the Board of Directors, we hope to continue this dialogue in an effort to ensure the best possible outcome for Zendesk shareholders." Janus Henderson owns 4.94% of Zendesk's outstanding shares, according to Bloomberg.

10:00 EST Sonendo rises 11.1% - Sonendo is up 11.1%, or 75c to $7.50.

10:00 EST Fortune 500 insurance company expands scope of services with Innodata - Innodata announced that a Fortune 500 insurance company has expanded its scope of services with Innodata to support its medical record predictive model development. The expansion adds approximately $700,000 of anticipated one-time revenue to the revenue estimates previously announced on September 15, 2021 of approximately $3M of one-time revenue and $800,000 per year of ongoing annual revenue.

09:47 EST Nomad Royalty falls -8.7% - Nomad Royalty is down -8.7%, or -69c to $7.28.

09:47 EST Philips falls -14.6% - Philips is down -14.6%, or -$5.67 to $33.10.

09:47 EST Planet Labs rises 9.6% - Planet Labs is up 9.6%, or 54c to $6.18.

09:47 EST Fathom rises 17.9% - Fathom is up 17.9%, or 95c to $6.26.

09:42 EST VINE Stock trading resumes

09:39 EST Altimar Acquisition Corp trading resumes

09:37 EST Immunome trading resumes

09:35 EST Altimar Acquisition Corp trading halted, volatility trading pause

09:34 EST VINE Stock trading halted, volatility trading pause

09:24 EST Vaxxinity announces first patient dosed in Part B Phase 1 trial of UB-312 - Vaxxinity announced that the first patient with Parkinson's disease has been dosed with UB-312 in Part B of a double-blinded, placebo-controlled Phase 1 clinical trial, following completion of Part A of the Phase 1 trial in healthy volunteers. UB-312 is a synthetic peptide vaccine targeting toxic forms of aggregated alpha-synuclein, a protein that plays a central role in synaptic functions and regulation of neurotransmitter release at the synapse. Mutations of aSyn increase the risk of developing PD and other synucleinopathies, including dementia with Lewy bodies as well as multiple system atrophy. UB-312 was granted an orphan designation for MSA by the European Medical Agency. The study is enrolling up to 20 patients with PD, Hoehn and Yahr stage less than or equal to III, at the Center for Human Drug Research in the Netherlands. Patients will be enrolled in one of two dosing cohorts with the primary objectives of safety and immunogenicity. The study will also assess exploratory biomarker endpoints for target engagement including Protein Misfolding Cyclic Amplification, supported by a grant from the Michael J. Fox Foundation, and in collaboration with Mayo Clinic and University of Texas.

09:16 EST CareCloud announces release of PrecisionBI version 7 - CareCloud announced the release of PrecisionBI version 7, which represents a fundamental platform upgrade to support existing clients and drive additional growth. With this release, PBI - CareCloud's healthcare analytics and business intelligence platform - is now fully cloud-based, far more scalable, and both browser and platform agnostic.

09:11 EST Darling Ingredients' Rousselot brand partners with TIBI - Darling Ingredients announced that its Rousselot Health brand has partnered with the Terasaki Institute for Biomedical Innovation, a California-based research institute focused on regenerative medicine. Through this strategic partnership, Rousselot and TIBI will collaborate on the development of gelatin-based therapies and their translation to the clinic. Rousselot will supply TIBI with X-Pure modified gelatins such as X-Pure GelMA, while exchanging insights on the behavior of gelatin in the institute's research and clinical trials. The partnership is effective from January 1st, 2022 and will have an initial duration of two years, fostering a close collaboration between TIBI's experts and Rousselot's experts in collagen- and gelatin-based biomaterials.

09:10 EST AMD announces AWS expands AMD EPYC processor-based offerings - AMD announced Amazon Web Services has expanded its AMD EPYC processor-based offerings with the general availability of the new Amazon EC2 Hpc6a instances, which are purpose-built for high performance computing workloads in the cloud. According to AWS, Amazon EC2 Hpc6a instances deliver up to 65 percent better price-performance compared to similar Amazon EC2 instances. Hpc6a will help customers run their most compute-intensive HPC workloads like, genomics, computational fluid dynamics, weather forecasting, financial risk modeling, EDA for semiconductor design, computer-aided engineering, and seismic imaging.

09:08 EST Vicor appoints Joshi as Global Automotive Segment Director - Vicor announced the appointment of Chinmaya Joshi as Global Automotive Segment Director. Chinmaya joins Vicor from the Jaguar Land Rover group where he served as a Senior Manager for powertrain power electronics. Joshi's primary role at Vicor will be to support the expansion of the OEM customer base, tier-one suppliers and automotive system partners through high-density modular solutions for electrification.

09:06 EST Oscar Health hires Ranmali Bopitiya as Chief Legal Officer - Oscar Health announced that it has hired Ranmali Bopitiya as its new Chief Legal Officer, effective January 31, . Ranmali will serve on Oscar's leadership team and will report to Chief Executive Officer and co-founder, Mario Schlosser. "Having spent close to two decades in healthcare, Ranmali brings a depth of experience that will support our work at Oscar as we continue to grow and innovate," said Mario Schlosser, CEO and co-founder at Oscar. "Her passion for improving access to high quality, affordable healthcare makes her a natural fit for Oscar and we are thrilled to bring on a new leader who will undoubtedly advocate for our mission." Ranmali joins Oscar from Everside Health, one of the largest Comments taken from Q earnings conference call.

09:05 EST Boeing selects Collins as next-generation lavatory supplier for 737 family - The Boeing Company (BA) has selected Collins Aerospace, a Raytheon Technologies (RTX) business to be the long-term provider of next-generation lavatories for the 737 family of aircraft. The new lavatory incorporates a modular design and customization opportunities for trim, finish and lighting and includes touchless functionality, the latest micro-LED lighting technology and a centralized computing system to optimize the passenger experience, improve airline operability and help pave the way for future technology integration. The next-generation lavatory is expected to be available on new 737 airplanes beginning in 2025, with installation available in 12 separate airplane locations and several different lavatory variations to choose from, including an accessible lavatory for passengers of all mobilities.

09:03 EST Taboola renews long-term contract with Siamsport.co.th - Taboola announced a renewal of its long-term partnership with Siamsport.co.th, Thailand's largest sports website, under Siam Sports Syndicate Public Company Limited. The deal marks a decade in partnership between Taboola and Siamsport.co.th. Siamsport.co.th continues to use Taboola technology to power content recommendations on its sports destination, including Taboola Feed. The publisher will also begin testing Taboola's e-commerce offerings through its recent acquisition of Connexity, to enhance its revenue growth strategy as well. Adam Singolda, CEO and founder, Taboola, said, "Siam Sports has built a strong legacy in providing comprehensive sports coverage for a large reader base in Thailand. Over our mutual decade-long partnership, they have shown real innovation in adopting new ways to grow, through recommendations, and most recently testing e-commerce solutions. We look forward to continuing to grow together."

09:02 EST Starboard nominates four director candidates for election to Huntsman board - Starboard Value, one of the largest shareholders of Huntsman, with an ownership interest of approximately 8.6% of the company's outstanding shares, announced that it has nominated a slate of four highly qualified director candidates for election to the Huntsman Board of Directors at the company's 2022 Annual Meeting of Shareholders. Starboard also announced that it has delivered a letter to Peter Huntsman, CEO and Chairman of the Board, with a copy to the company's board. Reference Link

09:02 EST Outbrain partners with Vivo to provide recommendations across browser newsfeeds - Outbrain announces an agreement with Vivo, a global technology company, to power Vivo's browser newsfeed with native content. Vivo will utilize Outbrain's OB News, which relies on content from Outbrain's publisher network and allows partners to tap into a stream of editorial content from these sites at no extra cost alongside trusted native monetization. "We continue to work with top-tier OEMs to be the premier business partner in the industry," says Stephanie Himoff, VP of Publishers at Outbrain. "Utilizing our best-in-class recommendation technology, such as OB News, to help partners optimize their engagement and monetization journey is something we continue to pride ourselves in as we work with Vivo to put our recommendations in front of audiences across the world."

09:00 EST 51Job trading resumes

08:46 EST NBT Bancorp launches NBT iSelect Account - NBT Bank is now offering the NBT iSelect Account, certified by the national Cities for Financial Empowerment Fund as meeting the Bank On National Account Standards. In addition to no monthly charges for maintenance, inactivity or dormancy, no overdraft fees and no minimum balance requirement, the NBT iSelect Account is an ideal choice for those who have no banking history or are struggling to maintain a checking account. NBT iSelect Account holders will also have access to an NBT Bank debit card and digital banking services.

08:45 EST Lixte Biotechnology announces filing of patent application on LB-100 - Lixte Biotechnology reported that its the recent collaboration with the Netherlands Cancer Institute, NKI, Amsterdam and Stichting Oncode Institute, Utrecht has led to an initial joint patent application covering LB-100 combination therapy with one of several other investigational compounds. Lixte, NKI and Oncode Institute believe that the combination therapy would provide unexpectedly strong synergistic anti-cancer effects in cancer patients. John Kovach, MD, the founder and CEO of Lixte, commented "The new findings support the hypothesis advanced by Professor Bernards at the NKI (Dias and Bernards, Mol Onc, 2021) that rather than the usual therapeutic approach to cancer - inhibiting overactive pathways that drive cancer growth - further stimulation of those pathways can overwhelm the cancer cells, rendering them exceptionally vulnerable to particular stress-targeted drugs, while sparing the normal cells. This 'paradoxical intervention' is truly groundbreaking and may be applicable to a broad range of cancers."

08:44 EST Paltalk rolls out content moderation software - Paltalk is pleased to announce the integration of Hive Automated Content Moderation Solutions into its Paltalk and Camfrog platforms. Paltalk is taking the next step to ensure a safe experience for its users by cracking down on spam and objectionable content. Hive uses powerful AI to detect offensive video, audio, and text through online content moderation. Through the Hive software, Paltalk will screen user-generated content in its video chat rooms. Paltalk will also leverage the text moderation feature of the Hive software platform to moderate its new "Paltalk Feed" feature to ensure it is being utilized safely. Paltalk expects to detect content across multiple model classes in 16 languages, including profanity, NSFW, personal data, drugs, sexual, violence, cyberbullying, hate, and spam. From the Hive dashboard, Paltalk administrators will be able to adjust the parameters of the AI to detect objectionable content of images, gifs, memes, videos, WEBP, speech-to-text audio, text strings, and text in images. The Company hopes that the powerful new tool will help curate a clean and positive user experience and ensure the Paltalk community is contributing content safe for everyone. Camfrog is currently using Hive and Paltalk is expected to be fully integrated with Hive by the end of the month.

08:42 EST Procaps Group to buy 86,000 sq. ft. pharmaceutical Florida production facility - Procaps Group announced the closing of an asset purchase agreement to acquire an 86,000 sq. ft. pharmaceutical production facility located in West Palm Beach, Florida with production capacity of approximately 1.8B capsules per year for its iCDMO business unit, and is expected to increase Procaps Group's product development capabilities by more than 70%. The pharmaceutical production facility was purchased from Strides Pharma a U.S. subsidiary of the Indian-based pharmaceutical corporation, the Strides Group. The facility is USFDA approved and, in addition to the manufacturing capabilities, it offers development and analytical testing capacities, which we believe will become an important alternative for new pharmaceutical and OTC developments in highly regulated markets worldwide. Core assets included in the acquisition were several Softgel encapsulation lines, new critical support systems, automated packaging line capabilities, as well as development facilities including pilot and scale up capabilities. Procaps Group expects the facility to begin operations in May of 2022.

08:41 EST Tenax Therapeutics granted US patent for subcutaneous use of TNX-102 - Tenax Therapeutics announced that the United States Patent and Trademark Office, USPTO, has granted a patent for the company's subcutaneous formulation of levosimendan, TNX-102, which is currently being developed for the treatment of pulmonary hypertension associated with left heart failure. On January 4, 2022, Tenax Therapeutics was issued US Pat. No. 11,213,524, entitled PHARMACEUTICAL COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION OF LEVOSIMENDAN, which is directed towards the use of levosimendan via subcutaneous administration for treating a subject having a health condition of any kind, such as heart failure, pulmonary hypertension including PH-HFpEF, chronic kidney disease, stroke, or other health conditions. The patent is expected to expire no earlier than 2039, exclusive of any possible extensions. "Extending patent protection for our lead drug candidates continues to be an important strategic focus for Tenax," said Christopher Giordano, President and Chief Executive Officer of Tenax Therapeutics. "The issuance of the '524 patent represents a key expansion of our IP portfolio, and we expect to secure additional patent protections for our lead drug programs to help build significant future value for our shareholders as we advance our lead drug candidates into pivotal Phase 3 testing."

08:39 EST Tomi Environmental Solutions provides SteraMist system to On Demand - TOMI Environmental Solutions is assisting the decontamination efforts of On Demand Pharmaceuticals by providing its SteraMist Environmental Systems for use at On Demand Pharmaceutical's modular cleanroom. The Defense Advanced Research Projects Agency, DARPA, developed TOMI BIT, the industry's only low-grade hydrogen peroxide-based solution capable of delivering six-log kill with a dwell time of seconds, without compromising human health or adversely affecting medical instruments, lab equipment or sensitive electronics. The pairing of a DARPA-funded medicine manufacturing initiative with a DARPA-developed disinfection and decontamination technology creates a powerful and unique partnership. Elissa Shane, TOMI Chief Operating Officer, states, "We are pleased to partner with a DARPA-funded innovative technology company, On Demand Pharmaceuticals. Both TOMI and On Demand share the vision of revolutionizing their respective industries, through the development of enhanced technology to promote health and safety. We look forward to continuing our partnership and our mutual mission to innovate for a safer world."

08:38 EST Midwest Energy Emissions secures multi-year contract renewal - Midwest Energy Emissions announced the signing of a two-year contract renewal with an estimated annual value in excess of $2.5M. Under the extended supply contract, ME2C will continue supplying its patented Sorbent Enhancement Additive technologies for mercury emissions capture.

08:36 EST Document Security acquires medical office building in Florida - DSS announced its majority-owned subsidiary, American Medical REIT has acquired a tenanted 21,900 square foot medical office building in Winter Haven, Florida. Palm Medical Center, the primary tenant of the Winter Haven medical office building, leases nearly 19,000 sq. ft. of the property and has six years remaining on its lease with three five-year options to renew. "While other areas within commercial real estate have been impacted by the ongoing pandemic, medical real estate has demonstrated considerable resiliency," stated Frank Heuszel, DSS CEO. "We are thrilled to further expand our medical real estate operations with the addition of the Winter Haven facility to our growing AMRE portfolio. AMRE, launched in March 2020, now owns more than 380,000 sq. ft. of high-quality healthcare assets across the US, providing a formidable foundation for our operations as we seek to further accelerate growth and build long-term value for our shareholders."

08:34 EST Athenex announces agreement with ImmunityBio on Dunkirk facility - Athenex (ATNX) announced that it has entered into a definitive agreement for ImmunityBio (IBRX) to assume its leasehold interest in a manufacturing facility in Dunkirk, New York, and certain related assets for approximately $38M, subject to adjustment at closing. Proceeds from the sale will be used to service the Company's debt obligations and for other general corporate purposes. The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2022. Upon the closing, ImmunityBio will assume all capital expenditure and hiring obligations of Athenex pursuant to its agreements with New York State. Athenex will continue to operate its existing Athenex Pharmaceutical Division, APD, and Athenex Pharmaceutical Solutions, APS, divisions. Athenex has not assigned any of its rights to its corporate headquarters in Buffalo, New York and will retain all of its rights and obligations with respect to its corporate headquarters. ImmunityBio has entered into a preliminary agreement with Athenex to allow APS the ability to manufacture its 503B products at the Dunkirk facility and the parties plan to enter into a definitive preferred contract manufacturing agreement.

08:33 EST Jennifer Aniston, Idorsia partner for 'Seize the Night & Day' campaign - Idorsia and Idorsia Pharmaceuticals, US announced its partnership with actor and director/producer Jennifer Aniston to launch Seize the Night & Day, an integrated educational campaign aimed at revealing insomnia's dual impact that affects both nights and days. The national initiative sheds light on the reality of insomnia for the millions of Americans living with this very real, but often overlooked medical condition. Idorsia and Jen have forged a multi-year collaboration with the shared goal of informing, inspiring and empowering people to take the first steps towards quality sleep through education, actionable information and community support.

08:32 EST Otonomo Technologies appoints Fred Kohout as Chief Marketing Officer - Otonomo Technologies announced the appointment of Fred Kohout as Chief Marketing Officer, CMO. Kohout will be charged with "scaling Otonomo's brand to demand engine to capitalize on the immense market opportunity represented by connected vehicle data and mobility intelligence," the company said. Kohout has worked in the technology sector for more than three decades during which time he has served as the Chief Marketing Officer of Cray, Inc., UC4 and Tagsys RFID.

08:29 EST 51Job trading halted, news pending

08:26 EST Osisko Development announces drilling results from Cariboo project - Osisko Development announced drilling results from the 2021 exploration and category conversion drill campaign at its Cariboo Gold Project in central British Columbia. Summary: A total of 28,000 meters were drilled in 92 holes at Lowhee Zone on Barkerville Mountain in 2021. Recent assay results include holes BM-21-052 to BM-21-080. BM-21-072 intersected a mineralized vein corridor with visible gold and cosalite that assayed 50.11 g/t Au over 7.50 meters including high grade samples of 630.00 g/t Au over 0.55 meter and 48.80 g/t Au over 0.55 meter. BM-21-062 assayed 227.00 g/t Au over 0.50 meter, located in the southeastern portion of the Lowhee Zone, further indicating exploration potential outside of the known veins. BM-21-071 intersected mineralized vein corridors of 21.35 g/t Au over 6.75 meters including a sample of 61.40 g/t Au over 0.85 meter within a modelled vein corridor. Additional high grade samples include 89.90 g/t Au over 0.60 meter in hole BM-21-056, 95.10 g/t Au over 0.70 meter in hole BM-21-058 and 94.00 g/t Au over 0.50 meter in hole BM-21-069. Assay Highlights 57.10 g/t Au over 0.50 meter in hole BM-21-052 including 46.60 g/t Au over 0.50 meter; 10.51 g/t Au over 5.65 meters in hole BM-21-053. 10.18 g/t Au over 4.65 meters in hole BM-21-053 including 45.50 g/t Au over 0.70 meter; 23.90 g/t Au over 1.45 meters in hole BM-21-053; 51.10 g/t Au over 0.50 meter in hole BM-21-054. 13.62 g/t Au over 3.00 meters in hole BM-21-056 including; 55.10 g/t Au over 0.50 meter; 7.42 g/t Au over 4.30 meters in hole BM-21-056; 89.90 g/t Au over 0.60 meter in hole BM-21-056.17.51 g/t Au over 4.20 meters in hole BM-21-058 including 95.10 g/t Au over 0.70 meter; 7.66 g/t Au over 8.20 meters in hole BM-21-060. 8.38 g/t Au over 8.00 meters in hole BM-21-061 including;72.60 g/t Au over 0.50 meter; 11.65 g/t Au over 2.90 meters in hole BM-21-061. 227.00 g/t Au over 0.50 meter in hole BM-21-062. 8.24 g/t Au over 4.85 meters in hole BM-21-062 including 57.70 g/t Au over 0.50 meter; 10.97 g/t Au over 4.25 meters in hole BM-21-063; 16.09 g/t Au over 5.95 meters in hole BM-21-064 including 65.00 g/t Au over 0.65 meter; 62.80 g/t Au over 0.55 meter. 28.10 g/t Au over 1.55 meters in hole BM-21-065 including 80.70 g/t Au over 0.50 meter; 75.50 g/t Au over 0.60 meter in hole BM-21-068; 94.00 g/t Au over 0.50 meter in hole BM-21-069. 21.35 g/t Au over 6.75 meters in hole BM-21-071 including 61.40 g/t Au over 0.85 meter;60.50 g/t Au over 0.50 meter in hole BM-21-071.50.11 g/t Au over 7.50 meters in hole BM-21-072 including 630.00 g/t Au over 0.55 meter and; 48.80 g/t Au over 0.55 meter. 7.45 g/t Au over 5.30 meters in hole BM-21-077. The vein corridors at Lowhee are the same style of mineralization as seen on our Island Mountain and Cow Mountain deposits- mineralized quartz veins hosted within the sandstone. Vein corridors are defined as a high-density network of mineralized quartz veins within the axis of the last folding event and hosted within a brittle meta-sandstone or calcareous meta-sandstone. Vein corridors are modelled at a minimum thickness of 2.00 meters and average about 4.50 meters true width. Individual mineralized veins within these corridors have widths varying from centimeters to several meters and strike lengths from a few meters to over 50 meters. These corridors have been defined from surface to a vertical depth averaging 300 meters and remain open for expansion at depth and along strike. Gold grades are intimately associated with quartz vein-hosted pyrite as well as pyritic, intensely silicified wall rock haloes in close proximity to the veins. True widths are estimated to be 60% to 75% of reported core length intervals. Intervals not recovered by drilling were assigned zero grade. Top cuts have not been applied to high grade assays.

08:21 EST FuelCell's Long Island, NY project commences conditional commercial operation - FuelCell Energy announced the completion of site construction and commencement of conditional commercial operation of its 7.4 megawatt SureSource fuel cell project located in Yaphank, Long Island, in New York. "We are excited to be in commercial operation of our fuel cell platform in the Town of Brookhaven, New York," commented Jason Few, President and Chief Executive Officer, FuelCell Energy. "We are executing on our promise to enable electrical resiliency and to deliver needed clean base load power to central Long Island, while reducing above ground risk associated with long distance high voltage transmission lines. Utilizing three of our fuel cell platforms, we will deliver to the grid 24/7 power that is enough to power approximately 7,500 homes from a footprint slightly larger than a couple of tennis courts." In conjunction with the project achieving commercial operation, Franklin Park has funded the remaining commitment under the previously announced tax equity arrangement, bringing the total investment in the project to $12.4M.

08:19 EST LifeMD announces acquisition of Cleared - LifeMD announced it has acquired Cleared, a nationwide allergy telehealth platform. "This acquisition represents a major step forward for LifeMD's mission of redefining and elevating American healthcare. Cleared is a transformational addition to our growing portfolio of telehealth capabilities and moves us beyond treating lifestyle conditions into chronic conditions with large addressable market demand," said LifeMD Chairman and CEO Justin Schreiber. "Cleared is at a stage of rapid growth. We're excited to work with their talented team to continue advancing the way Americans with allergies and respiratory conditions receive treatment." Under the terms of the agreement, LifeMD will acquire all outstanding shares of Cleared at closing in exchange for a $460,000 upfront cash payment, and non-contingent milestone payments for total of $3.46M. LifeMD will purchase a convertible note from a strategic pharmaceutical investor for $507,000. The acquisition is subject to customary closing conditions, including applicable regulatory approvals and is expected to close in the first quarter of 2022.

08:16 EST Global Crossing Airlines appoints Doreen DePastino as EVP, customer service - Global Crossing Airlines Group, announces the appointment of Doreen DePastino as EVP of Customer Service with responsibility for Inflight Services, Ramp and Station Operations. In addition, Ms. DePastino will serve as President of GlobalX Ground Team, LLC., GlobalX's wholly-owned ground services subsidiary. Ms. DePastino comes to GlobalX with over 35 years of experience in the airline industry with successful tenures at major international airlines, including start-up airlines. She previously served as the Vice President of Inflight for Emirates, Hawaiian Airlines, and LAN. She has been on the certification teams of JetBlue, Virgin America, and most recently Breeze Airways, where she led the Inflight and Station Operations teams.

08:15 EST Falcon Minerals trading resumes

08:13 EST Hepion Pharmaceuticals announces passing of director Thomas Adams - It is with profound sadness that Hepion Pharmaceuticals, announces the passing of Thomas Adams, Ph.D., a member of its Board of Directors. Dr. Adams died of natural causes on January 9, 2022. A seasoned biotechnology veteran, Dr. Adams was appointed to Hepion's Board in September 2016.

08:11 EST Immix Biopharma announces study data on IMX-110 - Immix Biopharma announced study data showing that ImmixBio's lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer - soft tissue sarcoma, STS, mouse study, surpassing the STS standard of care doxorubicin's 0% response rate in the same mouse study. The responses were assessed by RECIST 1.1 criteria applied to mice, with progression assessed after one cycle of treatment in a study funded by ImmixBio and conducted by a major STS oncology treatment center. "We strive to test our drug candidates in the most realistic, challenging animal models available," said Ilya Rachman, MD PhD, CEO of ImmixBio. "We are thrilled to see that in this first-line-therapy resistant STS model that IMX-110 showed significant activity. We believe this study is a preview of what our SMARxT Platform generating Tissue-Specific Therapeutics can do, a distinct alternative to the traditional 'single target, single mutation' development model."

08:09 EST Brainsway announces multiple publications on Deep TMS system treating OCD - BrainsWay announced key research data published in two peer-reviewed industry journals highlighting the durability and cost-effectiveness of its proprietary Deep TMS treatment for patients coping with obsessive-compulsive disorder, OCD. While prior research has demonstrated the safety and efficacy of Deep TMS in treating OCD, a recent study published in Brain Stimulation now shows the durability of Deep TMS and the significant reduction in functional disability. Additionally, positive data published in the Journal of Psychiatric Research support the cost-effectiveness of Deep TMS relative to other available treatment options for OCD. To evaluate the durability of the Deep TMS OCD treatment, clinical sites from the Company's trial, as well as those that contributed post-marketing data, conducted follow up assessments with patients that had met response criteria following treatment with the H7 Coil. Data revealed that of the 60 subjects evaluated from seven clinical sites, 52 demonstrated durability of one year or more, 26 of which showed two or more years of durability. Moreover, the data showed that patients exhibited a significant reduction in disability. Self-reported unproductive days per week dropped from 5.5 days to 1.8 days. Furthermore, positive data recently published in the Journal of Psychiatric Research demonstrated the relative cost-effectiveness of Deep TMS for refractory OCD patients when compared with other treatments within the treatment continuum.

08:08 EST Viveon Health Acquisition, Suneva Medical announce merger agreement - Suneva Medical and Viveon Health Acquisition Corp. announced that they have entered into a definitive merger agreement. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE under the symbol "RNEW." The pro forma equity valuation of the combined company is expected to be approximately $511M. VHAQ raised approximately $201M in connection with its IPO, which is now held in a trust account at Morgan Stanley with Continental Stock Transfer & Trust Company acting as trustee. Under the terms of the proposed transaction, VHAQ will issue 25M shares to current security holders of Suneva. Current Suneva security holders may also receive up to 12M earn out shares - 4M shares if the volume weighted average share price over any twenty trading days during a thirty day period exceeds $12.50 before the second year anniversary of the closing; 4M shares if the volume weighted average share price over any twenty trading days during a thirty day period exceeds $15.00 before the third year anniversary of the closing; and 4M shares if the volume weighted average share price over any twenty trading days during a thirty day period exceeds $17.50 before the five year anniversary of the closing. Furthermore, VHAQ's sponsor agreed to shift approximately 1.4M of its currently held sponsor shares to earn out shares and approximately 5.1M of its currently held sponsor warrants to earn out warrants, subject to same terms as company Earn Out Shares. The transaction, which has been approved by the Boards of Directors of Suneva and Viveon Health, is subject to approval by Suneva's stockholders, Viveon Health's stockholders and other customary closing conditions. The proposed business combination is expected to be completed in the first half of 2022.

08:08 EST Mainz Biomed names Michele Pedrocchi to strategic advisory board - Mainz Biomed N.V. (MYNZ) announced the appointment of Dr. Michele Pedrocchi to its Strategic Advisory Board. "Having Michele join our Strategic Advisory Board is a fantastic addition given his prolific background in the in vitro diagnostics space," commented Guido Baechler, CEO of Mainz Biomed. "Michele's vast experience launching IVD products in multiple international markets is especially timely for our flagship product, ColoAlert which is in the early stage of its commercial lifecycle, and I'm looking forward to his counsel and direction as we expand ColoAlert's commercial imprint across Europe and other international territories." During his tenure at Roche (RHHBY), Dr. Pedrocchi held senior leadership positions across corporate strategy, commercial and business development, including serving as Global Head of Strategy and Business Development for Diagnostics.

08:06 EST Heat Biologics announces new PTX-35 preclinical data, update on HS-110 - Heat Biologics announced promising new preclinical data regarding PTX-35 has been accepted for publication in the American Journal of Transplantation. Key Findings: a single dose of the preclinical version of PTX-35, was able to expand regulatory T cells and significantly improve disease and graft survival outcomes; Chemically induced pancreatic failure could be partially reversed when mice were transplanted with beta-cell islet allografts and treated with mPTX-35; Disease protection in preclinical models was correlated with a significant expansion of Tregs and protection of the allograft; Long-term surviving grafts showed a marked increase in Treg infiltration which directly correlated with mPTX-35 agonist activity. Jeff Wolf, Chief Executive Officer of Heat, commented, "We are very encouraged by these results showing pronounced Treg expansion and significantly prolonged graft survival compared to control...We are also making significant progress with HS-110 and expect to file for an End of Phase 2 meeting with the FDA this quarter. Our goal for this meeting is to discuss potential Phase 3 registration pathways for HS-110. Although this submission is taking longer than expected, we believe we have prepared a very comprehensive package and look forward to the FDA's feedback."

08:05 EST Hemisphere Media strikes multi-year carriage agreement with FuboTV - Hemisphere Media Group (HMTV) announced that it has struck a multi-year carriage agreement with fuboTV (FUBO). As a result of the partnership, all five Hemisphere cable networks-WAPA America, Cinelatino, Pasiones, CentroAmericaTV and Television Dominicana, which serve the U.S. Hispanic/Latino market at large and cater to specific segments within the community with targeted, culturally relevant content-will be available in HD to subscribers of fuboTV's Latino channel plan in the U.S. and Puerto Rico in Q1 of 2022. The partnership will give subscribers access to the Hemisphere networks' vast content offering, which includes top-rated news and entertainment programming from Puerto Rico, blockbusters and critically acclaimed films from Mexico, Latin America, Spain, and the Caribbean, hit international telenovelas and drama series, and sports programming and critical news from Central America and the Dominican Republic.

08:04 EST Shaw Communications expects closing of Rogers transaction in 1H22 - sjrOn March 15, 2021, Shaw announced that it entered into an arrangement agreement with Rogers Communications, under which Rogers will acquire all of Shaw's issued and outstanding Class A Participating Shares and Class B Non-Voting Participating Shares in a transaction valued at approximately $26 billion, inclusive of approximately $6 billion of Shaw debt. Holders of Class A Shares and Class B Shares will receive $40.50 per share in cash. The Shaw Family Shareholders will receive 60% of the consideration for their shares in the form of Class B Non-Voting Shares of Rogers on the basis of the volume-weighted average trading price for the Rogers Shares for the 10 trading days ending March 12, 2021, and the balance in cash. The Transaction is being implemented by way of a court-approved plan of arrangement under the Business Corporations Act. At the special meeting of Shaw shareholders held on May 20, 2021, the Company obtained approval of the plan of arrangement by the holders of Shaw's Class A Shares and Class B Shares in the manner required by the interim order granted by the Court of Queen's Bench of Alberta on April 19, 2021. On May 25, 2021, the Court of Queen's Bench of Alberta issued a final order approving the plan of arrangement. The Transaction remains subject to other customary closing conditions including approvals from certain Canadian regulators. Shaw and Rogers are working cooperatively and constructively with the Competition Bureau, Innovation, Science and Economic Development Canada and the Canadian Radio-television and Telecommunications Commission in order to secure the requisite approvals. Subject to receipt of all required approvals and satisfaction of all closing conditions, closing of the Transaction is expected to occur in the first half of 2022.

08:03 EST electroCore's nVNS device receives Breakthrough Designation from FDA - electroCore announced that its gammaCore non-Invasive Vagus Nerve Stimulation, nVNS, device has received Breakthrough Designation from the U.S. Food and Drug Administration, FDA, for the treatment of posttraumatic stress disorder after showing a reduction of symptoms of PTSD by 31% when compared to sham. The Breakthrough Device Designation was supported, in part, by research from an Emory-Georgia Tech team led by J. Douglas Bremner, M.D. and Omer Inan, Ph.D. Their research shows nVNS blocks sympathetic and inflammatory responses to memories of traumatic events in patients with PTSD, modulates brain responses to traumatic memory, and reduces symptoms of PTSD by 31% when compared to a sham stimulation.

07:51 EST Desert Peak Minerals, Falcon Minerals to combine in all-stock transaction - Desert Peak Minerals and Falcon Minerals announced that they have entered into a definitive agreement to combine in an all-stock transaction which values the combined enterprise at $1.9B. The combination is expected to create a mineral and royalty company with a significant footprint in the Permian Basin and Eagle Ford. The combined company will remain focused on consolidating high-quality mineral and royalty positions in the Permian Basin while optimizing its existing asset base. The combined company will adopt a governance and compensation model. The components include a capital allocation model balanced between return of capital to shareholders and reinvestment for growth; aligning management with shareholders through compensation and other factors. Management will not receive cash incentive compensation, and the majority of equity incentive compensation will be determined by absolute total shareholder return over a three-year period. The combined company will be managed by the Desert Peak team and led by Desert Peak's current CEO, Christopher Conoscenti. Noam Lockshin, a Partner at Kimmeridge, Desert Peak's and the combined company's largest equityholder, will serve as chairman of the board of directors. Following closing, the new board of directors will consist of eight members, who are currently expected to be: Noam Lockshin, Christopher Conoscenti, Erik Belz, Allen Li, Claire Harvey, Steven Jones, Morris Clark and Alice Gould. At the closing, Desert Peak will become a subsidiary of Falcon's operating partnership, or OpCo. The combined company will retain Falcon's "Up-C" structure, and Desert Peak's equityholders will receive 235M shares of Class C common stock, which number shall be adjusted in connection with the reverse stock split described below, with voting rights in the combined company and a corresponding number of limited partner units representing economic interests in OpCo. Desert Peak's equityholders may receive additional equity consideration, subject to certain exceptions, to the extent that, at the closing, Desert Peak's net debt is less than $140M. Upon completion of the transaction, assuming no adjustments to the equity consideration for Desert Peak's net debt, Desert Peak's equityholders will own approximately 73% and existing Falcon shareholders will own approximately 27% of the combined company. Based on the closing price of Falcon's Class A common stock of $5.45 on January 11, the combined company, including the value of OpCo limited partnership units not owned by Falcon, will have an initial equity market capitalization of approximately $1.76B and enterprise value of approximately $1.92B, including Class A and Class C common stock. Immediately prior to the closing of the transaction, subject to the approval of Falcon's shareholders, Falcon will execute a 1-for-4 reverse stock split. After giving effect to the reverse stock split and the proposed merger, the aggregate number of shares of Class A and Class C common stock outstanding is expected to be approximately 80M shares. The combination was approved by a Transaction Committee of Falcon's board comprised solely of disinterested directors, by the Falcon board and by Desert Peak's equityholders. The transaction is expected to close in the second quarter of 2022, subject to the approval of Falcon shareholders, certain regulatory approvals and satisfaction of other customary closing conditions. Blackstone, which currently owns 40.6% of the voting power of Falcon, has entered into a support agreement obligating it to vote in favor of the transaction.

07:40 EST Falcon Minerals trading halted, news pending

07:37 EST Cyteir Therapeutics doses first patient in CYT-0851 trial - Cyteir Therapeutics announced that the first patient has been dosed in a Phase 1 trial evaluating CYT-0851 in combination with three standard-of-care chemotherapy regimens in both hematologic malignancies and solid tumors.

07:33 EST Crinetics to present corporate, clinical update at JPM Healthcare Conference - Crinetics Pharmaceuticals announced that Scott Struthers, Ph.D., founder & CEO of Crinetics, will provide a company update at the 40th annual J.P. Morgan Healthcare Conference today, Wednesday, January 12th at 4:30 PM Eastern Time / 1:30 PM Pacific Time. During his presentation, Dr. Struthers will discuss Crinetics' key priorities and anticipated milestones for 2022. These include: Continued progress in the two ongoing Phase 3 PATHFNDR trials of paltusotine in acromegaly. Both trials remain on track and topline data is expected in 2023. The initiation of patient dosing in a Phase 2 trial of paltusotine in patients with carcinoid syndrome associated with neuroendocrine tumors, which is expected in 2022. Reporting Phase 1 multiple ascending dose data for CRN04894, an investigational, oral, nonpeptide adrenocorticotropic hormone antagonist being developed for the treatment of Cushing's disease and congenital adrenal hyperplasia, which is expected in 1Q 2022. The initiation of a Phase 2 trial of CRN04894, which is expected in 2H 2022. Reporting Phase 1 MAD data for CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 agonist being developed for the treatment of congenital hyperinsulinism, which is expected in 1Q 2022. The initiation of a Phase 2 trial of CRN04777, which is expected in 2H 2022. The initiation of IND-enabling studies for a parathyroid receptor type-1 antagonist, which is expected in 2022. Target indications for this program potentially include hyperparathyroidism and humoral hypercalcemia of malignancy.

07:32 EST Zai announces first patient treated in Greater China in PANOVA-3 Phase 3 trial - Zai Lab Limited announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase 3 pivotal trial of Tumor Treating Fields in patients with pancreatic cancer. "Pancreatic cancer is a common, highly aggressive form of gastrointestinal cancer, with an estimated five-year survival rate of only about 7% in China," said Alan Sandler, M.D., President, Head of Global Development, Oncology, at Zai Lab. "As the majority of cases have progressed to an advanced stage, there remains an urgent clinical need for more effective treatment options. Tumor Treating Fields has already been approved in the U.S. for glioblastoma and mesothelioma and in China for glioblastoma, and we believe that it represents a promising therapeutic approach for patients with pancreatic cancer as well." PANOVA-3 is a Phase 3 trial evaluating the efficacy of Tumor Treating Fields administered concomitantly with gemcitabine and nab-paclitaxel as front-line treatment for patients with unresectable, locally advanced pancreatic cancer.

07:18 EST Howard Hughes names Carlos Olea as CFO, effective January 12 - Howard Hughes announced that Carlos Olea has been appointed as the company's CFO, effective January 12. Olea becomes CFO at a time of escalating growth and strong financial performance across the company's acclaimed portfolio of large-scale master planned communities and mixed-use properties. Olea has been with The Howard Hughes Corporation since 2017 and has served as the company's Chief Accounting Officer since 2019, overseeing the financial accounting strategy for the nation's largest portfolio of MPCs during a time of outstanding growth. Prior to joining HHC, Olea served as Chief Accounting Officer at Carr Properties, a Washington, D.C.-based owner-operator and developer.

07:14 EST GoldMining's La Mina Project receives positive Preliminary Economic Assessment - GoldMining announced results of a positive Preliminary Economic Assessment - PEA - on the La Mina Project located in Antioquia, Colombia. The PEA provides a base case assessment for a mining operation with additional potential available through proposed exploration of the adjacent La Garrucha deposit. The Project would produce over 1 million gold equivalent ounces over a 10.4-year mine life. Production averaging 102,000 gold equivalent ounces per year over the fully operating years. The Project would produce over 165 million pounds of copper and over 600,000 ounces of silver. The Project generates a pre-tax net present value - NPV - of $340M at a 5% discount rate and an after-tax NPV of $232M with an internal rate or return of 14.5% using metal prices of $1,600 per ounce gold, $21 per ounce silver and $3.39 per pound copper. After-tax unit cash cost of $497 per gold ounce and All-In Sustaining Cost of $698 per gold ounce. Reports low capital intensity of $299.5M with a 10,000 ton per day concentrator fed by a low strip ratio open pit mining operation.

07:10 EST IMV Inc. announces first patient dosed in VITALIZE trial - IMV Inc. (IMV) announced a first patient dosed in the VITALIZE Phase 2B clinical trial. VITALIZE will further evaluate the clinical benefit of IMV's lead compound, maveropepimut-S, in combination with Merck's (MRK) anti-PD-1 therapy, Keytruda, in patients with relapsed/refractory diffuse large B cell lymphoma. The contribution of low dose cyclophosphamide as an immune modulator will also be evaluated in this trial.

07:09 EST Castle Biosciences publishes sequencing panel study for melanoma analysis - Castle Biosciences announced the publication of a study demonstrating that the combined application of DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq allows for highly accurate analysis of RNA and DNA from a single biopsy sample for patients with uveal melanoma. DecisionDx-UMSeq is Castle's 7-gene test that uses next-generation sequencing, NGS, to identify somatic mutations relevant to uveal melanoma. The sequencing panel identifies hotspot mutations in the genes GNAQ, GNA11, CYSLTR2, PLCB4 and SF3B1, mutations in exons 1-2 of EIF1AX and mutations across all coding exons of the BAP1 gene. This information, together with results from the DecisionDx-UM gene expression profile, GEP, test, is designed to help build a comprehensive genomic profile of an individual UM tumor from a single biopsy, which can then be used to inform patient care. DecisionDx-UM is Castle's 15-GEP test that uses an individual patient's tumor biology to predict individual risk of metastasis. DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the United States.

07:08 EST Bigg Digital Assets' Netcoins partners with BBTV to launch Pay To Crypto - BIGG Digital Assets (BBKCF), owner of Netcoins, is pleased to announce a non-exclusive partnership with BBTV Holdings (BBTVF) to launch Pay To Crypto, a premium solution to pay BBTV creators in cryptocurrencies. BBTV is a global media and technology company headquartered in Vancouver, Canada. The Company's mission is to help content creators become more successful. With creators ranging from individuals to global media brands, BBTV provides comprehensive, end-to-end solutions to increase viewership and drive revenue powered by its innovative technology, while allowing creators to focus on their core competency - content creation. In January 2021, BBTV had the second most unique monthly viewers among digital platforms, with more than 600 million globally who consumed more than 50 billion minutes of video content, the most among media companies. By leveraging Netcoins' Restricted Dealer License, as a legal and regulated Crypto Trading Platform in Canada, BBTV will be able to quickly and seamlessly pay their content creators in crypto. This offering uses Netcoins Platform as a Service model, whereby Netcoins enables 3rd party partners to enter the crypto economy for faster and easier payments or trading, with their own customer base.

07:05 EST Berkshire Grey introduces Reverse Logistics solution - Berkshire Grey introduced its Reverse Logistics solution to help retailers accelerate the resale of returned goods and improve labor utilization in the returns process. Projections indicate that by the end of January, consumers will return approximately $120 billion of goods following the holiday season, creating a significant inventory and cost challenge for retail. By implementing Berkshire Grey's Reverse Logistics solution for returns processing, eCommerce providers and retailers can reduce the time to recirculate returned items back onto the shelf and optimize labor productivity, ultimately improving profitability.

07:04 EST Embraer to sell subsidiaries EEM, EEC to Aernnova Aerospace for $172M - Embraer, in compliance with CVM Resolution 44/2021, informs its shareholders and the market that on January 11, the company, through its subsidiary Embraer Portugal S.A., entered into a binding contract for the sale of all of the shares of its wholly-owned subsidiaries Embraer Portugal Estruturas Metalicas S.A. and Embraer Portugal Estruturas em Compositos S.A. to Aernnova Aerospace, SAU, headquartered in Spain, for the reference price of $172M, subject to the usual adjustments for this type of transaction on the closing date. EEM and EEC are currently dedicated to supplying certain components used in the manufacture of aircraft by the company and by Embraer Executive Aircraft, LLC. The company hereby informs that, after the closing of the Transaction, Aernnova will undertake the operation of EEM's and EEC's industrial plants and will ensure the level of production and supply of such components for Embraer aircraft portfolio. The Transaction, which has been unanimously approved by the company's board of directors, is expected to close in the first quarter, following the fulfillment of certain conditions precedent.

07:02 EST atai Life Sciences' IND for PCN-101 approved by FDA - atai Life Sciences announced that the FDA has given Investigational New Drug - IND - clearance to conduct a clinical DDI study of PCN-101 - R-ketamine -. atai plans to initiate the study early this year through its platform company Perception Neuroscience. The properties of PCN-101 could offer a differentiated profile to currently available antidepressants and address key patient needs, including the potential of rapid action and anti-suicidal effect. R-ketamine has demonstrated the potential to offer longer durability and a potentially more favorable safety and tolerability profile than S-ketamine, which could enable the potential for at-home use. An estimated 100 million people live with TRD globally, representing a third of people with depression. This clinical DDI trial will advance alongside an existing Phase 2a proof-of-concept trial in TRD, recently initiated in Europe. Additionally, atai anticipates running a bioavailability study in 2022. atai will use the results of the DDI study in conjunction with clinical pharmacokinetic data to advance the development of PCN-101 in TRD.

06:56 EST Xylem names Dorothy Capers as General Counsel - Xylem announced the appointment of Dorothy Capers as Senior Vice President, General Counsel, effective February 7. Current General Counsel, Claudia Toussaint, has assumed the dual responsibilities of Chief Human Resources and Sustainability Officer, a newly combined position supporting the company's strategy to further integrate its human capital and ESG strategies. Capers will join Xylem's senior leadership team, reporting to Patrick Decker, President and CEO. Dorothy Capers has served as Executive Vice President, Global General Counsel and Corporate Secretary of the National Express Group, a transport provider, for the last four years, previously serving as General Counsel for the North America region.

06:50 EST Lazard reports preliminary AUM approximately $273.7B as of December 31, 2021 - Lazard reported that its preliminary assets under management as of December 31, 2021 totaled approximately $273.7B. The month's AUM included market appreciation of $8.5B, net outflows of $3B and foreign exchange appreciation of $0.9B. Preliminary average assets under management for the quarter ended December 31, 2021 were $273.5B.

06:49 EST First American to acquire Mother Lode Holding Company, terms not disclosed - First American announced the signing of an agreement for First American's acquisition of Mother Lode Holding Company, a California-based provider of title insurance, underwriting and escrow services for residential and commercial real estate transactions with 17 operating subsidiaries throughout the U.S., including its principal subsidiary Placer Title Company. The closing of the transaction is subject to regulatory approvals and the satisfaction of customary closing conditions.

06:47 EST Zymeworks Chief Medical Officer buys 5K shares of common stock - In a regulatory filing, Zymeworks said its Chief Medical Officer Neil Josephson bought 5K shares of common stock on January 7th in total transaction size of $71.4K.

06:38 EST Jefferies Financial Group raises quarterly dividend to 30c per share - Richard Handler, CEO, and Brian Friedman, President said, "In light of our performance and prospects, as well as our limited need for incremental equity capital, our Board of Directors has increased our quarterly dividend to 30c per share, a 140% increase from two years ago. We will continue also to return capital to shareholders via share buybacks as well as, if financial conditions and circumstances permit, in-kind distributions or special cash dividends as we continue to wind down the legacy merchant banking portfolio." The dividend is payable on February 25 to record holders of Jefferies common shares on February 14.

06:36 EST New Gold reports Q4 production 111,574 gold equivalent ounces - Total production for Q4 was 111,574 gold equivalent ounces consisting of 81,072 ounces of gold, 214,030 ounces of silver and 14.2M pounds of copper. For the year, production was 418,933 gold equivalent ounces consisting of 286,921 ounces of gold, 867,961 ounces of silver and 61.7M pounds of copper. The company achieved the updated consolidated gold equivalent guidance range. "2021 was not without its challenges for New Gold, but we continued to execute on our plans, with the fourth quarter representing our strongest quarter of the year, allowing us to meet our updated consolidated gold equivalent production guidance", stated Renaud Adams, president and CEO. "Rainy River's fourth quarter production was up 16% compared to the third quarter, representing Rainy River's strongest quarter over the last two years, despite a 3-day mill shutdown in December, mainly driven by improved grade due to lower contribution from the East Lobe. At New Afton, the team was able to execute on its plans and achieved both gold and copper production guidance."

06:35 EST Datto appoints Brooke Cunningham as Chief Marketing Officer - Datto has appointed Brooke Cunningham as new Chief Marketing Officer. Cunningham has worked at companies in software including Splunk, CA Technologies, SAP, and Qlik.

06:33 EST Qiwi acquires Taxiaggregator SaaS platform - Qiwi has acquired Taxiaggregator, a SaaS platform that provides payment solutions and data analytics tool for taxi companies and taxi drivers. The platform allows drivers to see balances and order history from all aggregators consolidated in real time at a convenient interface. Qiwi and GuruTaxi launched its Taxiaggregator SaaS platform for taxi market back in 2019. Taxiaggregator platform serves about 2,800 taxi companies and more than 308 thousand drivers. The company's subsidiary, QIWI Technologies, acquired the platform and other intellectual property followed by the transfer of the client base and the team of the project. As a result, the company owns 80% of QIWI Technologies with the remaining 20% owned by the Founder of Taxiaggregator, Alexander Merzlikin. The deal was approved by the Board of Directors and expected to be finalized in Q1.

06:12 EST Lantern Pharma expands collaboration with DTB of National Cancer Institute - Lantern Pharma announced it has expanded its collaboration agreement with the Developmental Therapeutics Branch, or DTB, of the National Cancer Institute, or NCI, of the National Institutes of Health. The expansion of this collaboration comes after identifying several gene signatures that predict a potential response of a patient's tumor to Lantern's drug candidates, LP-184 and LP-284. LP-184 is being pursued as a new therapy across a range of genetically defined solid tumors, including pancreatic cancer and Glioblastoma Multiforme. LP-184 was presented as a novel agent effective in GBM at Society of Neuro-Oncology in November of 2021. LP-284 is being developed as a new therapy for certain leukemias and lymphomas as presented for the first time in December at the 2021 ASH Annual Meeting.

06:10 EST DoorDash CEO Tony Xu to join Meta's board, Zuckerberg says - Mark Zuckerberg announced in a Facebook post that Tony Xu is joining Meta's (MVRS) board of directors. Xu is co-founder and CEO of DoorDash (DASH). Zuckerberg said: "I've always thought it's important to have great tech leaders on our board, and Tony has direct experience both running a tech company and solving complex challenges in commerce. I look forward to learning from Tony's perspective as we build towards the metaverse." Reference Link

06:04 EST Immuron receives $3.43M award from Department of Defense for Travelan test - Immuron announced the funding of a new research agreement with the U.S Department of Defense. The focus of this new agreement is aimed at testing and confirming the efficacy of a single larger dose regimen of Travelan in a controlled human infection model clinical study using the enterotoxigenic Escherichia coli strain H10407. This single larger dosing regime is potentially more amenable for use in military populations. Results of the proposed clinical study will also inform on dosing in the pivotal Phase 3 registration trials for BLA licensure. A project kickoff meeting for this award has been scheduled for the end of January. Two company sponsored clinical studies have demonstrated that Travelan conferred 84%-90% protective efficacy against moderate to severe diarrhea upon challenge with ETEC in comparison to a placebo. Infectious diarrhea is the most common illness reported by US troops deployed overseas.

05:30 EST Philips expands Respironics recall notification - Philips Respironics is increasing the field action provision by around EUR 225M, mainly due to the higher volume of devices now requiring remediation and increased supply costs. Philips Respironics expanded the scope to certain older devices in the interest of patients and in alignment with the relevant competent authorities and now expects to remediate a total of approximately 5.2M registered devices globally. "Patient well-being is at the heart of everything we do at Philips, and we aim to get a solution to patients as fast as possible," said Frans van Houten. "To date, Philips Respironics has produced a total of approximately 1.5 million repair kits and replacement devices, of which approximately 700,000 have reached customers. I am also encouraged by the positive VOC test results to date for the first-generation DreamStation devices, which we published in December 2021 [3]."

05:13 EST Hepsiburada, Intel launch DigitalSME - Hepsiburada (HEPS) and Intel (INTC) announced the launch of DigitalSME, a program providing support to small and medium-size enterprises, or SMEs, in Turkey. DigitalSME will enable businesses to develop their e-commerce technology infrastructure, accelerate their digital transformation, and strengthen their businesses. The program will expand access to the digital economy by providing tools for new SMEs and those moving into e-commerce by offering training, discounted hardware, software tools, and grants for HepsiAd, Hepsiburada's advertising platform.